Intra-articular Pulsed Radiofrequency With Steroids Injection Versus Intra-articular Steroids Injection in Chronic Sacroiliac Joint Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-01

Study Completion Date

2021-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The sacroiliac joint is Located between the pelvis and base of the spine, the sacroiliac joints are strong, stable joints that allow for little movement. While these joints do not bend like a knuckle or knee, they are susceptible to degenerative arthritis. Sacroiliac joint pain is one of the most common causes of chronic low back pain, accounting for 10% to 27% of patients with chronic lower back pain. It is known to be caused by abnormal motion in this joint, namely, too much motion or too little motion. Patients with pain experience various degrees of pain in the low back, groin, buttock, or posterior thigh.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Unguided Sacroiliac Injection: Effect on Refractory Buttock Pain in Patients With Spondyloarthropathies

NCT00829543

Spondylarthropathy

UNKNOWN EARLY_PHASE1

Platelet-rich Plasma in the Sacroiliac Joint

NCT03744234

Sacroiliac Joint Arthritis

COMPLETED NA

Methotrexate Adherence in Rheumatoid Arthritis Patients

NCT05535686

Rheumatoid Arthritis

COMPLETED

Evaluating the Role of Intra-articular Injections of Platelet Rich Plasma (PRP) in Patients With Rheumatoid Arthritis.

NCT04264494

RA - Rheumatoid Arthritis

UNKNOWN NA

Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein

NCT02364479

Spondyloarthritis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The pain starts when the Sacroiliac joint gets inflamed. There are several reasons it could happen. It could be hurt when playing sports or if fall down.

Sometimes start hurting when the ligaments that hold the SI joint together are damaged, which may make the joint move abnormally. The pain associated with sacroiliitis most commonly occurs in the buttocks and lower back. It can also affect the legs, groin and even the feet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Management

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group A

receive intraarticular radiofrequency + methylprednisolone (30 mg)

Group Type EXPERIMENTAL

intraarticular radiofrequency + intraarticular methylprednisolone

Intervention Type DRUG

intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)

group C

receive intraarticular methylprednisolone (30 mg)

Group Type EXPERIMENTAL

intraarticular methylprednisolone

Intervention Type DRUG

intraarticular methylprednisolone (30 mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intraarticular radiofrequency + intraarticular methylprednisolone

intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)

Intervention Type DRUG

intraarticular methylprednisolone

intraarticular methylprednisolone (30 mg)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients must have chronic pain more than 6 months and have failed medical treatment.

Exclusion Criteria

* Infection at the site of injection
* Opioids addiction
* Coagulopathy or another bleeding diathesis
* Those who refuse to participate in the study
* Ankylosing Spondylitis patients

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No